Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 11INDUSTRY 2NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1

Conditions

von Hippel-Lindau Disease 1Hemangioblastoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × vatalanib × Clear all
NCT00052013 2017-03-06

Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584

Novartis

Phase 2 Completed
11 enrolled

von Hippel-Lindau Disease, Hemangioblastoma

NCT00160043 2014-12-16

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.

Bayer

Phase 2 Completed
112 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡